Clinical Trial Update: Post-Authorization Long-Term Safety Study of LUTATHERA

View source ↗

Summary

Update on the post-authorization long-term safety study of LUTATHERA for neuroendocrine tumors, with study status listed as ACTIVE_NOT_RECRUITING.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Neuroendocrine Tumors

Drugs mentioned

• LUTATHERA (Lutetium Lu-177 dotatate)

Snippet

Sponsor: Advanced Accelerator Applications | Conditions: Neuroendocrine Tumors | Status: ACTIVE_NOT_RECRUITING